The FDA is expanding its private sector collaborations to advance its understanding of real world data and evidence. Does this mean that it will begin to approve new drugs and expand labeling on the basis of physician and patient experience, rather than solely on randomized clinical trial data?
FDA Leverages Private Sector Technology-Based Tools In Its Embrace Of Real World Evidence
